Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
---|---|---|---|---|
20654 | Lorundrostat | 1820940-17-7 | 98% Min. | |
Lorundrostat is an aldosterone synthase inhibitor. | ||||
20625 | LEO-32731 | 1353546-86-7 | 98% Min. | |
LEO-32731 is a bioactive chemical. | ||||
20588 | Losmapimod | 585543-15-3 | 98% Min. | |
Losmapimod, also know as GW856553 or GW856553X or GSK-AHAB, is a drug developed by Gl | ||||
20577 | LY3522348 | 2568608-48-8 | 98% Min. | |
20551 | Lin281632 | 108825-65-6 | 98% Min. | |
Lin28 1632, is a RNA binding protein Lin28 inhibitor. Lin281632 promotes mESC differe | ||||
20531 | LUNA18 | unknown | 98% Min. | |
LUNA18 is a N-alkyl-rich cyclic peptide | ||||
20477 | LQZ-7I | 195822-23-2 | 98% Min. | |
LQZ-7I is a malarial protease PfSUB1 inhibitor. LQZ-7I showed significantly improved | ||||
20461 | LSN2463359 | 1401031-52-4 | 98% Min. | |
LSN2463359 is a novel positive allosteric modulators of the mGlu₅ receptor. | ||||
20438 | LFM-A13 | 244240-24-2 | 98% Min. | |
LFM-A13 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). LF | ||||
20266 | Linzagolix | 935283-04-8 | ≧98.0% | |
Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially | ||||
21244 | LY-3475070 | 2375815-63-5 | 98% Min. | |
LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM. LY3475070 Alo | ||||
210507 | LP-261 | 915412-67-8 | ≧98.0% | |
LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine sit | ||||
21225 | LM11A-31 HCl | 1243259-19-9 | 98% Min. | |
20113001 | LVN84663 | 103784-66-3 | 98% Min. | |
LVN84663 is a useful reagent for determination of blood coagulating protease. It was | ||||
2091908 | LUN42518 | 47142-51-8 | 98% Min. | |
LUN42518, also known as Phentolamine Analogue 1, is an analogue of phentolamine. Phen | ||||
2073106 | Lerociclib HCl (G1T38 HCl) | 2097938-59-3 | ≧98.0% | |
Lerociclib HCl (G1T38)is a novel, selective,differentiated oral CDK4/6 inhibitor with | ||||
2071555 | Lobaplatin | 135558-11-1 | 98% Min. | |
Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes containin | ||||
2071524 | Lixivaptan | 168079-32-1 | 98% Min. | |
Lixivaptan, laso known as CRTX-080; VPA-985; WAY-VPA-985, is a potent, orally active, | ||||
2071505 | LAU159 | 2055050-87-6 | 98% Min. | |
LAU159 is a potent modulator of α6β3γ2 GABAA receptor. | ||||
2071502 | Lificiguat | 170632-47-0 | 98% Min. | |
Lificiguat, also known as YC-1, is a inhibitor of Hypoxia-inducible factor-1alpha (HI | ||||
20732 | Lanraplenib | 1800046-95-0 | 98% | |
Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor in develo | ||||
2061309 | Linperlisib free base | 1702816-75-8 | 98% Min. | |
Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ | ||||
2061307 | L006235 | 294623-49-7 | 98% Min. | |
L006235 is a potent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays | ||||
2051510 | LML-134 | 1542135-76-1 | 98% | |
LML134 is an orally active and high selective Histamine 3 receptor (H3R) inverse agon | ||||
2042701 | LUT-014 | 2274819-46-2 | 98% Min. | |
LUT-014 is a B-Raf Inhibitor. Leveraging the paradoxical effect of B-Raf Inhibitors, | ||||
2041502 | LSZ102 | 2135600-76-7 | 98% Min. | |
LSZ102 is a potent ERα antagonist and degrader. LSZ102 showed ERα degradation IC50 | ||||
204502 | LUN42589 | 1848242-58-9 | 98% Min. | |
LUN42589, also known as PI3K/mTOR Inhibitor-2, is a potent dual pan-PI3K/mTOR inhibit | ||||
204302 | Lerociclib | 1628256-23-4 (free base) | 98% | |
Lerociclib , also known as G1T38, is an oral, potent and selective CDK4/6 inhibitor f | ||||
6111904 | Lemborexant (E-2006) | 1369764-02-2 | 98% Min. | |
Lemborexant(CAS 1369764-02-2)is a novel investigational small molecule that inhib | ||||
193262 | LY2794193 | 2173037-97-1 | >98% | |
LY2794193 is a highly potent and selective mGlu3 receptor agonist. |
Overnight Delivery
Fast & Safe Delivery Worldwide
Safety and Security
Intimate Service
Copyright 2015-2022 武汉永璨生物科技有限公司 版权所有 | 鄂ICP备17005301号-1